FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed are: combination for treatment of inflammatory disease, including R,R-glycopyrrolate, budesonide in combination with formoterol or with rolipram or their physiologically acceptable salts and pharmaceutical preparation of the same purpose, including combination of therapeutically efficient quantities of R,R-glycopyrrolate, budesonide in combination with therapeutically efficient quantity of formoterole or rolipram or their physiologically acceptable salts. Demonstrated is synergetic inhibition of more than 50% of secretion of TNF-alpha by combination of three active substances, which do not inhibit it individually or inhibit insignificantly, less than 5%.
EFFECT: combination and preparation can be applied for treatment of such inflammatory diseases, first, as bronchial asthma, chronic obstructive lung disease (COLD), rheumatic or autoimmune diseases.
16 cl, 2 dwg
